Aileron Therapeutics, Inc.
ALRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.00 | 0.02 | -0.00 |
| FCF Yield | -6.57% | -12,943.86% | -13.74% | -10.57% |
| EV / EBITDA | -8.96 | 0.83 | -6.69 | -0.80 |
| Quality | ||||
| ROIC | -11.45% | -13.80% | -10.86% | -75.94% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.64 | 0.94 | 1.12 | 0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 501,229.79% | 501,229.79% | 501,229.79% | 501,229.79% |
| Free Cash Flow Growth | 44.72% | -3.94% | -28.33% | -26.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.73 | 0.83 | 1.32 | 0.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -1,301.43 |